Cart
sales@molnova.com
JNK Inhibitor VIII
CAS No. 894804-07-0
JNK Inhibitor VIII( TCS JNK 6o )
Catalog No. M21993 CAS No. 894804-07-0
JNK Inhibitor VIII is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 110 | In Stock |
|
| 10MG | 177 | In Stock |
|
| 25MG | 312 | In Stock |
|
| 50MG | 464 | In Stock |
|
| 100MG | 662 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameJNK Inhibitor VIII
-
NoteResearch use only, not for human use.
-
Brief DescriptionJNK Inhibitor VIII is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively).
-
DescriptionJNK Inhibitor VIII is an ATP-competitive selective inhibitor of c-Jun N-terminal kinase (JNK)(IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively).
-
In Vitro——
-
In Vivo——
-
SynonymsTCS JNK 6o
-
PathwayMAPK/ERK Signaling
-
TargetJNK
-
RecptorJNK1:2 nM (Ki)|JNK1:45 nM (IC50)|JNK2:4 nM (Ki)|JNK2:160 nM (IC50)|JNK3:52 nM (Ki)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number894804-07-0
-
Formula Weight356.38
-
Molecular FormulaC18H20N4O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (701.50 mM)
-
SMILESCCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Szczepankiewicz BG, et al. Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
molnova catalog
related products
-
GSK2879552 2HCl
GSK2879552 is an orally available, irreversible inhibitor of lysine specific demethylase 1 (LSD1), with potential antineoplastic activity.
-
CC-90001
CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.
-
Tanzisertib
Tanzisertib (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1] and it blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis.
